J& J Announces Positive Phase 3 Trial Results for Nipocalimab in gMG
Johnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with
Read moreJohnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreThe approval is supported by robust clinical evidence, including results from a global Phase III trial. Omlyclo® is the first
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read moreimusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read moreThe Behring Campus Eystrup is a cutting-edge research facility specialising in animal immunology, antibody development, and preclinical research. Located at
Read moreVertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read morePfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read moreIovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read moreThe European Commission (EC) has granted marketing authorisation for Roche’s Tecentriq® SC (atezolizumab) making it the first European Union PD-(L)1
Read more